Actively Recruiting
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Led by Northwestern University · Updated on 2025-05-02
1000
Participants Needed
1
Research Sites
974 weeks
Total Duration
On this page
Sponsors
N
Northwestern University
Lead Sponsor
T
The Scripps Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
CONDITIONS
Official Title
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female recipients of all races, 18 years of age or older
- Patients undergoing primary or subsequent living or deceased donor liver transplantation
- Subject and/or guardian must be able to provide informed consent
- Subject and/or guardian must be able to comply with the study protocol
You will not qualify if you...
- Inability or unwillingness of a participant and/or guardian to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Actively Recruiting
Research Team
M
Misael Villegas, BA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here